LncRNA Information | |||||
---|---|---|---|---|---|
ID | EL0046 | Name | AB209630 | Aliases | N/A |
Species | Mus musculus | Chromosome | N/A | Start site | N/A |
End site | N/A | Chain | N/A | Exon NO. | N/A |
Assembly | N/A | Class | lncRNA | NCBI accession | N/A |
Ensembl | N/A | Sequence | N/A | Peptide-related | N/A |
CircRNA | N/A | Exosomal | N/A | Structure | N/A |
Disease | |||||||||
---|---|---|---|---|---|---|---|---|---|
Disease | Drug/chemo/stress | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | ||
pancreatic cancer | gemcitabine | qRT-PCR | tumor tissue, CFPAC-1 cells, the CD133+ cancer stem cells | down-regulated | interaction | Qingyihuaji formula reverses gemcitabine resistant human pancreatic cancer through regulate lncRNA AB209630/miR-373/EphB2-NANOG signals. | 31147453 |
Interaction | |||||||||
---|---|---|---|---|---|---|---|---|---|
Interaction target | Level of interaction | Type of interaction | Methods | Description | PMID | ||||
miR-373 | RNA-RNA | regulation | N/A | QYHJ could effectivly enhance the antihuman pancreatic tumor activity of GEM, which may be through inhibiting pancreatic cancer stem cell differentiation by lncRNA AB209630/miR-373/EphB2-NANOG signaling pathway. | 31147453 | ||||
Display: |
|